Risultati ricerca pubblicazioni

PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines

pubblicato su: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY - 2018

Camero S, Ceccarelli S, De Felice F, Marampon, Mannarino O, Camicia L, Vescarelli E, Pontecorvi P, Pizer B, Shukla R, Schiavetti A, Mollace Mg, Pizzuti Antonio, Tombolini V, Marchese C, Megiorni F, Dominici C

First-line treatment with olaparib for early stage BRCA-positive ovarian cancer: May it be possible? Hypothesis potentially generating a line of research

pubblicato su: CANCER MANAGEMENT AND RESEARCH - 2020

Tomao F., Boccia S. M., Chirra M., Palaia I., Petrella M. C., Di Donato V., Colombo N., Panici P. B., Sassu C. M.

Incorporating parp-inhibitors in primary and recurrent ovarian cancer. A meta-analysis of 12 phase II/III randomized controlled trials

pubblicato su: CANCER TREATMENT REVIEWS - 2020

Ruscito I., Bellati F., Ray-Coquard I., Mirza M. R., du Bois A., Gasparri M. L., Costanzi F., De Marco M. P., Nuti M., Caserta D., Pignata S., Dorigo O., Sehouli J., Braicu E. I.